Related references
Note: Only part of the references are listed.Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction
Luke W. Koblan et al.
NATURE BIOTECHNOLOGY (2018)
Optimized base editors enable efficient editing in cells, organoids and mice
Maria Paz Zafra et al.
NATURE BIOTECHNOLOGY (2018)
In vivo CRISPR editing with no detectable genome-wide off-target mutations
Pinar Akcakaya et al.
NATURE (2018)
In utero CRISPR-mediated therapeutic editing of metabolic genes
Avery C. Rossidis et al.
NATURE MEDICINE (2018)
Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent)
Mohamed K. M. Shakir et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Programmable base editing of A.T to G.C in genomic DNA without DNA cleavage
Nicole M. Gaudelli et al.
NATURE (2017)
Highly efficient RNA-guided base editing in mouse embryos
Kyoungmi Kim et al.
NATURE BIOTECHNOLOGY (2017)
Genome-wide target specificities of CRISPR RNA-guided programmable deaminases
Daesik Kim et al.
NATURE BIOTECHNOLOGY (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T: A base editors with higher efficiency and product purity
Alexis C. Komor et al.
SCIENCE ADVANCES (2017)
Management of patients with statin intolerance
Sabine Fischer et al.
ATHEROSCLEROSIS SUPPLEMENTS (2017)
In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing
Alexandra C. Chadwick et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report
Xiao Wang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Alexis C. Komor et al.
NATURE (2016)
Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems
Keiji Nishida et al.
SCIENCE (2016)
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia A Systematic Review and Meta-analysis
Eliano Pio Navarese et al.
ANNALS OF INTERNAL MEDICINE (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Characterization of the First PCSK9 Gain of Function Homozygote
Ana Catarina Alves et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
In vivo genome editing using Staphylococcus aureus Cas9
F. Ann Ran et al.
NATURE (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Statin Intolerance: Diagnosis and Remedies
Angela Pirillo et al.
CURRENT CARDIOLOGY REPORTS (2015)
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Shengdar Q. Tsai et al.
NATURE BIOTECHNOLOGY (2015)
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation
Hiroshi Mabuchi et al.
ATHEROSCLEROSIS (2014)
Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Qiurong Ding et al.
CIRCULATION RESEARCH (2014)
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE
Brandon Ason et al.
JOURNAL OF LIPID RESEARCH (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Chromosomal Translocations in Human Cells Are Generated by Canonical Nonhomologous End-Joining
Hind Ghezraoui et al.
MOLECULAR CELL (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
Marianne Abifadel et al.
ATHEROSCLEROSIS (2012)
Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis
S. Matthijs Boekholdt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
Allan D. Sniderman et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2011)
PCSK9: an emerging target for treatment of hypercholesterolemia
Christopher J. Duff et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Analyzing of high-density lipoprotein subfractions and low-density lipoprotein subfractions in human serum with anion-exchange chromatography
Yuji Hirowatari et al.
ATHEROSCLEROSIS (2008)
Unravelling the functional significance of PCSK9
Gilles Lambert
CURRENT OPINION IN LIPIDOLOGY (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
The impact of translocations and gene fusions on cancer causation
Felix Mitelman et al.
NATURE REVIEWS CANCER (2007)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Share Paper
